GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » KalVista Pharmaceuticals Inc (FRA:4XC1) » Definitions » Book Value per Share

KalVista Pharmaceuticals (FRA:4XC1) Book Value per Share : €3.70 (As of Jul. 2024)


View and export this data going back to 2016. Start your Free Trial

What is KalVista Pharmaceuticals Book Value per Share?

KalVista Pharmaceuticals's book value per share for the quarter that ended in Jul. 2024 was €3.70.

During the past 12 months, KalVista Pharmaceuticals's average Book Value Per Share Growth Rate was -1.40% per year. During the past 3 years, the average Book Value Per Share Growth Rate was -22.70% per year. During the past 5 years, the average Book Value Per Share Growth Rate was -2.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.

During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of KalVista Pharmaceuticals was 61.00% per year. The lowest was -22.70% per year. And the median was 11.85% per year.

KalVista Pharmaceuticals's current price is €9.60. Its book value per share for the quarter that ended in Jul. 2024 was €3.70. Hence, today's PB Ratio of KalVista Pharmaceuticals is 2.60.

During the past 13 years, the highest P/B Ratio of KalVista Pharmaceuticals was 13.10. The lowest was 0.29. And the median was 3.13.

Good Sign:

KalVista Pharmaceuticals Inc stock PB Ratio (=2.62) is close to 1-year low of 2.46


KalVista Pharmaceuticals Book Value per Share Historical Data

The historical data trend for KalVista Pharmaceuticals's Book Value per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

KalVista Pharmaceuticals Book Value per Share Chart

KalVista Pharmaceuticals Annual Data
Trend Apr15 Apr16 Apr17 Apr18 Apr19 Apr20 Apr21 Apr22 Apr23 Apr24
Book Value per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.32 8.80 6.98 4.30 4.53

KalVista Pharmaceuticals Quarterly Data
Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24
Book Value per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.68 3.15 2.35 4.53 3.70

Competitive Comparison of KalVista Pharmaceuticals's Book Value per Share

For the Biotechnology subindustry, KalVista Pharmaceuticals's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


KalVista Pharmaceuticals's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, KalVista Pharmaceuticals's PB Ratio distribution charts can be found below:

* The bar in red indicates where KalVista Pharmaceuticals's PB Ratio falls into.



KalVista Pharmaceuticals Book Value per Share Calculation

KalVista Pharmaceuticals's Book Value Per Share for the fiscal year that ended in Apr. 2024 is calculated as:

Book Value Per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(192.53-0.00)/42.52
=4.53

KalVista Pharmaceuticals's Book Value Per Share for the quarter that ended in Jul. 2024 is calculated as:

Book Value Per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(159.32-0.00)/43.08
=3.70

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Theoretically it is what the shareholders will receive if the company is liquidated. Total Stockholders Equity is a balance sheet item and equal to Total Assets less Total Liabilities of the company.

Book value may include intangible items which may come from the company's past acquisitions. Book value less intangibles is called Tangible Book.


KalVista Pharmaceuticals  (FRA:4XC1) Book Value per Share Explanation

Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.

For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.


KalVista Pharmaceuticals Book Value per Share Related Terms

Thank you for viewing the detailed overview of KalVista Pharmaceuticals's Book Value per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


KalVista Pharmaceuticals Business Description

Traded in Other Exchanges
Address
55 Cambridge Parkway, Suite 901 East, Cambridge, MA, USA, 02142
KalVista Pharmaceuticals Inc is a pharmaceutical company, which focuses on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema and diabetic macular edema; and oral plasma kallikrein inhibitors. Geographically it operates throughout the region of the United States.

KalVista Pharmaceuticals Headlines

No Headlines